PHASTAR announced the appointment of Cary Morrill as Chief People Officer.
Science 37 announced Elisa Cascade has joined the company and its senior executive team as Chief Product Officer. Additionally, Chris Ceppi has been appointed to serve as Chief Technology Officer. Science 37 also announced the appointment of Emily Rollins to its Board of Directors. Ms. Rollins will serve as the chairperson for the Audit Committee.
Certara, Inc. announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer.
Calyx announced that two of the world’s Top 5 pharmaceutical companies have chosen to continue using the Calyx Regulatory Information Management system.
Certara, Inc. announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award.
CluePoints announced it has been shortlisted for Clinical Advance of the Year - COVID-19 Pandemic Special Recognition Award at the Scrip Awards, as well as two Citeline Awards—´Best Sponsor-facing Technology Initiative´ and ´Excellence in Innovation in Response to COVID-19 - Clinical Trial Activities’.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.